"L'hôpital de la Garde et l'hôpital Clémenceau prennent en charge tous types de consultations à Toulon et La Seyne-sur-Mer. Une unité de soins de longue durée est présente ainsi qu'un accueil de jour pour les patients atteints d'Alzheimer."

During the past decade, Hôpital Sainte Musse conducted 37 clinical trials. In the 10-year time frame, 37 clinical trials started and 7 clinical trials were completed, i.e. on average, 18.9% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 6 clinical trials were completed. i.e. 40% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hôpital Sainte Musse" #1 sponsor was "Federation Francophone de Cancerologie Digestive" with 6 trials, followed by "Boehringer Ingelheim" with 3 trials sponsored, "Canadian Cancer Trials Group" with 2 trials sponsored, "Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer" with 2 trials sponsored and "Hoffmann-La Roche" with 2 trials sponsored. Other sponsors include 28 different institutions and companies that sponsored additional 35 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hôpital Sainte Musse" #1 collaborator was "Intergroupe Francophone de Cancerologie Thoracique" with 4 trials as a collaborator, "AstraZeneca" with 2 trials as a collaborator, "ARCAGY/ GINECO GROUP" with 1 trials as a collaborator, "AbbVie" with 1 trials as a collaborator and "Assistance Publique Hopitaux De Marseille" with 1 trials as a collaborator. Other collaborators include 44 different institutions and companies that were collaborators in the rest 54 trials.

According to Clinical.Site data, the most researched conditions in "Hôpital Sainte Musse" are "Schizophrenia" (4 trials), "Breast Cancer" (3 trials), "COVID-19" (2 trials), "Colorectal Cancer Metastatic" (2 trials) and "Non-small Cell Lung Cancer" (2 trials). Many other conditions were trialed in "Hôpital Sainte Musse" in a lesser frequency.

Most popular intervention types in "Hôpital Sainte Musse" are "Drug" (25 trials), "Other" (11 trials), "Biological" (2 trials), "Diagnostic Test" (2 trials) and "Genetic" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Bevacizumab" (3 trials), "Pembrolizumab" (3 trials), "Obinutuzumab" (2 trials) and "Panitumumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Hôpital Sainte Musse" are 46 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Hôpital Sainte Musse". undefined are not yet recruiting, 12 are recruiting, 11 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 23 completed trials in Hôpital Sainte Musse, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Hôpital Sainte Musse, 0 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 5 trials that are defined as “Not Applicable".